Npam-217

N/A

Report date: 2021/12/03 13:22:38
NME

Base Information

Drug NameNpam-217
Drug Alias NameNpam-217PMS-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor modulators
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesQingdao Pumeisheng Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQingdao Pumeisheng Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A